ExpreS2ion Biotech Holding AB (EXPRS2) AI Stock Analysis

• Market Cap: kr68.05M
• Dividend Yield: N/A
• Average Volume (3M): 25.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: -36.71%
• EPS Growth: 72.81%
• Country: SE
• Employees: 20
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -4.30
• Shares Outstanding: 2,658,346
• 10 Day Avg. Volume: 16,856
• 30 Day Avg. Volume: 25,474
• PEG Ratio: -0.04
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: kr22.50 ▼(-12.11%Downside)

ExpreS2ion Biotech Holding AB's overall stock score is primarily influenced by weak financial performance marked by significant net losses and negative cash flow. While technical analysis indicates some positive momentum, the lack of profitability and poor valuation metrics weigh heavily on the score. Without notable earnings call data or corporate events to offset these issues, the stock's score remains low.

ExpreS2ion Biotech Holding AB Business Overview & Revenue Model

Company Description

ExpreS2ion Biotech Holding AB (EXPRS2) is a biotechnology company focused on the development and commercialization of innovative technologies and products within the biopharmaceutical industry. The company specializes in protein production, utilizing its proprietary ExpreS2 platform, which is based on Drosophila S2 cells for the efficient and scalable expression of recombinant proteins. ExpreS2ion Biotech serves sectors such as vaccine development, diagnostics, and therapeutic protein production, providing solutions to both research institutions and the pharmaceutical industry.

How the Company Makes Money

ExpreS2ion Biotech Holding AB generates revenue through several streams, primarily by licensing its proprietary protein expression technology, the ExpreS2 platform, to pharmaceutical companies and research organizations. This licensing can involve upfront payments, milestone payments, and royalties based on the success of the products developed using their technology. Additionally, the company offers contract research services, where they undertake specific projects for clients, which also involves service fees. Partnerships with other biotech and pharmaceutical companies further contribute to its earnings, where collaborative research and development efforts can lead to shared revenue from co-developed products. The company may also receive funding from grants or research initiatives, contributing to its financial inflow.

ExpreS2ion Biotech Holding AB Financial Statement Overview

Summary

ExpreS2ion Biotech Holding AB is facing financial challenges with consistent net losses and negative cash flow. Despite a stable equity position and low debt levels, the company's inability to generate positive income and cash flow highlights operational inefficiencies and potential risks.

Income Statement

The company has experienced a decline in total revenue from 2023 to 2024, with a significant net loss, indicating poor profitability. The gross profit margin is negative due to higher costs than revenues. While revenue growth was positive from 2022 to 2023, it declined sharply from 2023 to 2024.

Balance Sheet

The equity ratio is moderate, reflecting a balanced but somewhat leveraged position. The debt-to-equity ratio is low, indicating limited reliance on debt. However, the return on equity is negative, showing inefficiency in generating profits from equity.

Cash Flow

The company has negative free cash flow, indicating challenges in generating cash from operations after capital expenditures. The operating cash flow to net income ratio is negative, showing cash inefficiency, despite a decrease in negative free cash flow from 2023 to 2024.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.01M	7.05M	5.09M	12.23M	5.26M
Gross Profit	-2.67M	3.40M	5.00K	4.72M	-843.00K
EBITDA	-64.34M	-102.45M	-124.49M	-46.38M	-28.47M
Net Income	-36.41M	-91.40M	-118.61M	-43.92M	-31.71M
Balance Sheet
Total Assets	104.53M	78.69M	137.36M	151.96M	118.86M
Cash, Cash Equivalents and Short-Term Investments	81.54M	57.60M	110.97M	138.88M	106.83M
Total Debt	360.00K	1.71M	1.85M	1.92M	2.38M
Total Liabilities	40.11M	13.33M	34.04M	11.61M	24.31M
Stockholders Equity	64.42M	65.36M	103.33M	140.35M	94.55M
Cash Flow
Free Cash Flow	-34.80M	-102.90M	-100.00M	-46.36M	-19.06M
Operating Cash Flow	-33.93M	-100.89M	-99.61M	-45.65M	-18.18M
Investing Cash Flow	21.27M	-2.02M	105.33M	-100.92M	-1.08M
Financing Cash Flow	34.87M	47.84M	61.46M	74.55M	123.38M

ExpreS2ion Biotech Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Positive. The current price of 25.6 is above the 20-day moving average (MA) of 23.37, above the 50-day MA of 21.58, and above the 200-day MA of 25.46, indicating a bullish trend. The MACD of 1.14 indicates Negative momentum. The RSI at 60.00 is Neutral, neither overbought nor oversold. The STOCH value of 71.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EXPRS2.

ExpreS2ion Biotech Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	€48.91M	―		78.14%	-94.12%	-25.83%
Sector *	50 Neutral	kr5.39B	12.66	-80.61%	5.12%	37.36%	27.71%
EXPRS2	49 Neutral	kr68.05M	―	-66.45%	―	-36.71%	72.81%
MODTX	42 Neutral	kr44.56M	―	-222.24%	―	―	58.36%
ONCOZ	41 Neutral	kr79.18M	―	-46.84%	―	―	45.38%
SPRINT	39 Underperform	kr53.18M	―	-147.64%	―	30.02%	-3985.71%
SPAGO	38 Underperform	kr104.81M	―	-105.78%	―	58.72%	70.69%